Atez/Bev	atezolizumab plus bevacizumab combination therapy
HCC	hepatocellular carcinoma
PFS	progression-free survival
ICI	immune checkpoint inhibitor
irAE	immune-related adverse event
RECIST	Response Evaluation Criteria in Solid Tumors
mRECIST	modified RECIST
CR	complete response
PR	partial response
SD	stable disease
PD	progressive disease
OS	overall survival
mALBI	modified albumin-bilirubin
OTU	operational taxonomic unit
IQR	interquartile range
AUC	area under the curve
ROC	receiver operating characteristic
PPI	proton pump inhibitor
P-CAB	potassium-competitive acid blocker
SCFA	short-chain fatty acid
UDCA	ursodeoxycholic acid